ContextVision (CONTX)

[kreinh]

Tar med en kommentar fra HO:

"På dagens investorpresentasjon sa Fredrik Palm at de ikke venter salg av INIFY® Prostate i 2021, men håpet at det kunne skje i 2022. Videre fikk han spørsmål om dette nye forretningsområdet ville kunne gå break even i løpet av 3-5 år, og etter en liten tenkepause sa han at han regnet med at det ville være en realitet i allefall i løpet av 5 år. Da har man vel også satt litt forventninger til kortsiktige resultater.

Det aller viktigste var å jobbe med nye produkter og muligheter slik at man i det lengre bildet har en robust og god produktportefølge.

Det gamle forretningsområdet som evt blir igjen i Contextvision mente han at kunne fortsette å øke ca 10% pr år opp til 150 mill i omsetning. Da vil jo dette være en potensiell liten pengemaskin."

Her bygges stein på stein. Det vil ta litt tid men verdien øker for hver kvartal.

[kreinh]

Synd at det ikke ble kontrakter etter evalueringen. Palm mener det ikke blir noen salg av INIFY Prostata før i 2022. Kanskje blir det mer fart i salg etter evalueringen i USA.

[riskypick]

Rimelig åpenbart at visibilitet på MI er solid. Her går det godt om dagen. Dersom MI leverer noe omkring det Fredrik forespeiler vil denne enheten Ila ett års tid aleine forsvare dagens mcap for Contx totalt. Etter mitt skjønn får man DP gratis med på kjøpet til dagens kurs. Akkurat som vi vet at MI går godt vet vi at DP trenger tid. Dette er nok imidlertid noe som kommer og konkurrent paige har investert store summer. Så ved en splittelse vil MI fremkomme som en low risk-medium/high reward aksje. DP blir type high risk-high reward.

[kreinh]

“USA skroter innreisenekt i november.”
Da får ContextVision mer fart på opptrappingen i USA med personlig kontakt uten pandemie restriksjoner. Venter snart tilbakemelding på evaluering av INIFY Prostate i USA. Den 6/7 ble det meldt om installasjon av INIFY Prostate på Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital og Richard J. Solove Research Institute (OSUCCC – James) i Columbus, OH, og ved Tufts Medical Center (Tufts MC), Boston, MA.
Spennende høst hvor vi også vil få mer info om utskillelsen av INIFY produktene i et eget selskap. Som tidligere sagt må man kunne oppfatte dette ønske som et resultat av de positive tilbakemeldingene fra hospitalene i Europa og de etter min mening kommende positive tilbakemeldinger fra hospitalene i USA.
Kontrakt inngåelser sier Palm vil komme.
(Antagelig etter innpassing i sykehus budsjettene.)

[kreinh]

Litt info mens vi venter…

Shareholders

ContextVision AB is listed on the Oslo Stock Exchange under ticker CONTX. The shareholder list was last updated August 31, 2021. Number of outstanding shares: 77,367,500

Monsun AS|23 000 000|29.73|
|Sven Günther-Hanssen|8 516 670|11.01|
|Martin Hedlund|8 316 660|10.75|
|Tauri AS|3 883 275|5.02|
|MP Pensjon|3 437 510|4.44|
|Bernt Stavland|2 424 000|3.13|
|Bras Kapital AS|2 100 000|2.71|
|VINTERSTUA AS|2 064 421|2.67|
|Anders Stavland|1 898 000|2.45|
|Danske Bank A/S|1 726 970|2.23|
|Svenska Handelsbanken AB|1 288 400|1.67|
|Per Stavland|1 272 030|1.64|
|Swedbank AB|928 088|1.20|
|J.P. Morgan Bank Luxembourg S.A.|842 547|1.09|
|Crown Hill Chartering|634 160|0.82|
|Kristian Sveen|568 550|0.73|
|Avanza Bank AB|534 147|0.69|
|Rune Skjelbred|530 222|0.69|
|CACEIS Bank|451 599|0.58|
|Carnegie Investment Bank AB|450 000|0.58|
|Others|12 500 251|16.16|
|Total outstanding shares|77 367 500|100|

Vi får sammenligne pr. 30 September

[kreinh]

Aksjonærer pr. 1 oktober 2021 (parantes pr. 1 September)

Monsun AS 23 000 000 29.73
Sven Günther-Hanssen 8 516 670 11.01
Martin Hedlund 8 316 660 10.75
Tauri AS 3 883 275 5.02
MP Pensjon 2 565 123 3.32 (3 437 510 4.44)
Bernt Stavland 2 260 000 2.92 (2 424 000 3.13)
State Street Bank and Trust Comp 2 197 823 2.84
VINTERSTUA AS 1 964 421 2.54 (2 064 421 2.67)
Anders Stavland 1 898 000 2.45
Bras Kapital AS 1 800 000 2.33 (2 100 000 2.71)
Danske Bank A/S 1 726 970 2.23
Svenska Handelsbanken AB 1 343 866 1.74
Per Stavland 1 252 030 1.62 (1 272 030 1.64)
Swedbank AB 936 286 1.21 (928 088 1.20)
J.P. Morgan Bank Luxembourg S.A. 863 491 1.12 (842 547 1.09)
Crown Hill Chartering 634 160 0.82
Avanza Bank AB 580 855 0.75 (534 147 0.69)
Kristian Sveen 514 950 0.67 (568 550 0.73)
Rune Skjelbred 491 754 0.64 (530 222 0.69)
CACEIS Bank 451 599 0.58

Carnegie Investment Bank AB 450 000 0.58 har gått ut av listen.
Ny er: State Street Bank and Trust Comp 2 197 823 2.84

Others 12 169 567

State Street Bank and Trust Company, more commonly known as State Street Global Services or simply Global Services, is a subsidiary of State Street Corporation organized as a trust company based in Massachusetts specializing in services to mutual funds and their advisers, collective investment funds, corporate and public pension funds, insurance companies, operating companies and non-profit organizations. Global Services is the largest custodian bank in the world.

[kreinh]

Man bør kanskje merke seg at State Street Bank viser interesse for selskapet. Noen som vet om de kan ha hatt mulighet til å vite om dette:

ContextVision announces agreement with two renowned US cancer centers for clinical evaluation of INIFY® Prostate

STOCKHOLM – July 6, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in Columbus, OH, and with Tufts Medical Center (Tufts MC), Boston, MA.

Principal investigators for the study are Professor Anil Parwani, M.D., Ph.D., M.B.A at OSUCCC – James and Ming Zhou, MD, PhD, Chair and Pathologist-in-Chief at Tufts MC. The study will evaluate how INIFY Prostate can improve the performance of resident diagnosis when reviewing prostate biopsy samples. Ground truth will be provided by the two principal investigators, world-renowned sub-specialists within prostate cancer.

INIFY is a powerful AI-based software that precisely outlines suspected cancerous areas in prostate biopsies, with unique, detailed pixel-level focus. Based on a patented annotation method used in training of the algorithms – MasterAnnotation – INIFY pre-sorts slides in a worst-first order, and comes with a user-friendly viewer designed for handling prostate biopsies.

“As president of the Digital Pathology Association and one of few sites in the US being fully digitalized, I’m eager to explore how the use of AI-based decision support tools can support prostate diagnosis, and potentially improve workflow,” says Anil Parwani, Director of Pathology Informatics and Director of the Digital Pathology Shared Resource at OSUCCC – James.

“At Tufts Medical Center, we are in the process of digitalizing pathology,” says Dr. Zhou, Chair and Pathologist-in-Chief at Tufts MC. ”Our department certainly would benefit from a tool to support high quality diagnosis and speed up this transition.”

“We are very excited and proud to have the opportunity to cooperate with two of the most respected pathologists within the society, and their clinics, for driving the digitalization process,” says Magnus Aurell, VP Business Unit Digital Pathology at ContextVision.

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. To learn more, visit cancer.osu.edu.

Tufts Medical Center is an exceptional, not-for-profit, 415 bed academic medical center that is home to both a full-service hospital for adults and Tufts Children’s Hospital. Tufts MC’s renowned research program ranks among the top 10 percent of independent hospitals to receive federal research funding. The Medical Center is the principle teaching hospital for Tufts University School of Medicine. The Department of Pathology and Laboratory Medicine includes more than 200 dedicated pathologists, medical technologists, medical technicians, phlebotomists and administrative staff who provide comprehensive diagnostic testing services in a wide variety of areas within anatomic and clinical pathology. The faculty members are engaged in cutting edge research that aims to translate bench research to bedside patient care.

I så fall ser de en mulighet for å komme inn tidlig i aksjen, før evalueringen er ferdig og de første kontraktene inngåes…

[kreinh]

State Street Bank har kommet inn siden siste kvartal presentasjon, kanskje mest i løpet av den siste måneden siden de nå vises på syvende plass. Store aksjeposter har byttet hender på denne tiden. Det meste har gått til høyere kurs enn dagens. Bulker på 60 - 70 tusen aksjer av gangen over børs, muligens avtalt på forhånd i en aksje som kan få store svingninger om noen vil inn uten “avtale”. Synsing fra mi side, men ikke helt uten substans tror jeg.

[kreinh]

2 uker igjen til Kvartalsrapport (3. kvartal). Anyone… Velkommen til ekkokammeret.
Forhåpentligvis mer info om utskillelsen av INIFY delen av ContextVision (AI).

[riskypick]

Bare å holde denne kreinh. Silent winner.

[kreinh]

Bulleye utdyper ytterligere om det videre løp for selskapet på HO.

[kreinh]

Nesten 100k aksjer gikk i dag klokken 11:47. State Street Bank som er på ferde?

[kreinh]

Ei uke igjen til Q3 presentasjonen. Etter forrige kvartals presentasjon var kursen 16% høyere enn nå. Ser ikke noen grunn til at vi ikke skal høyere enn dette. Aksjekursen ligger nå likt med det nivået var for et år siden. Det har skjedd mye positivt siden da og også noe kjempespennende. Spinnoff av AI/INIFY delen av selskapet vil gi mer verdi for dagens aksjonærer. Håper vi får mer info angående denne utskillelsen.
Manglende interesse for selskapet kommer nok av at vi skjeldent hører noe fra de. Mulig dette forandrer seg etterhvert. Tror det er lurt å være inne før oppdateringen kommer…

Stadig omsetning av poster på 70/100.000 aksjer gjør caset interessant.

[kreinh]

Robotene jobber iherdig for å skvise ut noen aksjer til tilbudspris.

[kreinh]

Kan vi vente resultat av evalueringen innen utgangen av året eller før. Selskapet har en spennende fremtid. Veldig grundig omtale av produktene ContextVision fører på deres webside: https://www.contextvision.com/

ContextVision announces agreement with two renowned US cancer centers for clinical evaluation of INIFY® Prostate
STOCKHOLM – July 6, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in Columbus, OH, and with Tufts Medical Center (Tufts MC), Boston, MA.

Principal investigators for the study are Professor Anil Parwani, M.D., Ph.D., M.B.A at OSUCCC – James and Ming Zhou, MD, PhD, Chair and Pathologist-in-Chief at Tufts MC. The study will evaluate how INIFY Prostate can improve the performance of resident diagnosis when reviewing prostate biopsy samples. Ground truth will be provided by the two principal investigators, world-renowned sub-specialists within prostate cancer.

INIFY is a powerful AI-based software that precisely outlines suspected cancerous areas in prostate biopsies, with unique, detailed pixel-level focus. Based on a patented annotation method used in training of the algorithms – MasterAnnotation – INIFY pre-sorts slides in a worst-first order, and comes with a user-friendly viewer designed for handling prostate biopsies.

“As president of the Digital Pathology Association and one of few sites in the US being fully digitalized, I’m eager to explore how the use of AI-based decision support tools can support prostate diagnosis, and potentially improve workflow,” says Anil Parwani, Director of Pathology Informatics and Director of the Digital Pathology Shared Resource at OSUCCC – James.

“At Tufts Medical Center, we are in the process of digitalizing pathology,” says Dr. Zhou, Chair and Pathologist-in-Chief at Tufts MC. ”Our department certainly would benefit from a tool to support high quality diagnosis and speed up this transition.”

“We are very excited and proud to have the opportunity to cooperate with two of the most respected pathologists within the society, and their clinics, for driving the digitalization process,” says Magnus Aurell, VP Business Unit Digital Pathology at ContextVision.

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. To learn more, visit cancer.osu.edu.

Tufts Medical Center is an exceptional, not-for-profit, 415 bed academic medical center that is home to both a full-service hospital for adults and Tufts Children’s Hospital. Tufts MC’s renowned research program ranks among the top 10 percent of independent hospitals to receive federal research funding. The Medical Center is the principle teaching hospital for Tufts University School of Medicine. The Department of Pathology and Laboratory Medicine includes more than 200 dedicated pathologists, medical technologists, medical technicians, phlebotomists and administrative staff who provide comprehensive diagnostic testing services in a wide variety of areas within anatomic and clinical pathology. The faculty members are engaged in cutting edge research that aims to translate bench research to bedside patient care.

[Bruskus]

INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers

STOCKHOLM – October 18, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that results from a US clinical evaluation were presented at the Pathology Visions Congress in Las Vegas, USA.

The evaluation was performed together with two independent pathologists, Anil Parwani, M.D., Ph.D., M.B.A. at Ohio State University Comprehensive Cancer Center (Columbus, Ohio), and Ming Zhou, M.D., Ph.D., Chair and Pathologist-in-Chief at Tufts Medical Center (Boston, Massachusetts). It showed that for images with small focus of cancer (≤1 mm), the INIFY algorithm identified all cancer glands and did not miss any. The sensitivity was 100% in these cases. Also, for images with larger cancer areas, outlining was very precise, with a sensitivity of 99.3 – 99.8%. For a decision support tool to be an effective companion in the clinical workflow, it is important that it does not identify too many false positives. In this evaluation, INIFY Prostate showed a high specificity of 96 – 98%.

“Many pathologists find signing out benign cases to be accompanied by the anxiety of having missed something important. Decision support tools that are reliable in finding even the smallest cancer foci can play an important role in increasing diagnostic confidence,” says Dr. Zhou.

Prostate biopsy slides from 30 unique patients from both Wexner and Tufts medical centers were scanned using three different scanners. Drs. Parwani and Zhou reviewed INIFY Prostate’s predictions of suspicious cancer areas in all scanned slides. The aim of the evaluation was to see whether the product’s performance differed depending on pathology lab (i.e., variations in slide preparation such as staining) or scanners used. It was concluded that INIFY Prostate works equally well on images from both labs, rendering very similar outcomes in terms of sensitivity and specificity. Thus, the INIFY predictions are robust.

“This is the first quality assurance study that has compared the performance of a prostate algorithm on images scanned on three different scanners side by side,” says Dr. Parwani.

INIFY is a powerful AI-based software that precisely outlines suspicious cancer areas in prostate biopsies, with unique, detailed pixel-level focus – a result of MasterAnnotation, a patented annotation method used in training of the algorithms.

“This result adds to several studies that confirms INIFY’s ability to support the pathologists in their daily clinical work,” says Magnus Aurell, VP Business Unit Digital Pathology at ContextVision.

[kreinh]

16.10.
“Kan vi vente resultat av evalueringen innen utgangen av året eller før. Selskapet har en spennende fremtid.”

Føler meg litt synsk nå.

[kreinh]

Det er ufattelig hvor lite interesse det er for selskapet. Det ser man på hvor lite respons en får på innleggene vi skriver både her og på HO. Mulig mange som sover i timen og ikke ser verdien i ContextVision. Det kan hende at andre våkne utlendinger vil skjønne at dette er gull og ikke bare State Street Bank som akkumulerer aksjer. Da kan det bli for seint for små aksjonærer å få del i en uunngåelig stigende aksjekurs.

[kreinh]

Hva kan vi vente av tall i morgen? Tallene for Q2 var gode og det i Korona tider:

“Very strong sales in 2Q
ContextVision released its 2Q21 report this morning. Sales came in at SEK 24.4m (the highest 2Q sales ever), which was 10% better than SEK 22.1m estimated by us. EBITDA was reported at around zero (SEK -0.1m) vs marginally positive figure (SEK 1.1m) in our model. Cash position was further strengthened and now stands above SEK 50m.”

Solid selskap. Ettersom jeg skjønner bruker de en ca 50 millioner i året i utviklingsutgifter. INIFY Prostate er ferdig utviklet og lunge og tarm står for tur. Skiller man ut denne delen i et eget selskap vil tallene for gjenstående virksomhet vise nevnte tall i overskudd. Da snakker vi utbytte.

[Secundum]

Tydeligvis ikke store forventninger, presses bra ned om dagen.